GCP
ATRA icon

GSA Capital Partners’s Atara Biotherapeutics ATRA Stock Holding History

GSA Capital Partners’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-26,213
Closed -$376K – 1670
2025
Q3 		$376K Buy
26,213
+6,622
+34% +$76.2K 0.03% 1055
2025
Q2 		$151K Buy
19,591
+206
+1% +$1.5K 0.01% 1570
2025
Q1 		$115K Buy
+19,385
New +$169K 0.01% 1480
2024
Q1 		– Sell
-31,375
Closed -$402K – 1595
2023
Q4 		$402K Buy
+31,375
New +$732K 0.03% 939
2023
Q2 		– Sell
-2,821
Closed -$205K – 1507
2023
Q1 		$205K Buy
2,821
+2,117
+301% +$205K 0.02% 1244
2022
Q4 		$58K Sell
704
-1,504
-68% -$157K 0.01% 1349
2022
Q3 		$209K Buy
+2,208
New +$248K 0.03% 1194
2022
Q2 		– Sell
-579
Closed -$134K – 1391
2022
Q1 		$134K Sell
579
-396
-41% -$126K 0.02% 1250
2021
Q4 		$384K Buy
+975
New +$410K 0.05% 767
2021
Q2 		– Sell
-520
Closed -$187K – 1311
2021
Q1 		$187K Buy
+520
New +$230K 0.03% 926

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

GSA Capital Partners's ATRA Position: Q4 2025 in Review

GSA Capital Partners sold out of Atara Biotherapeutics (ATRA) in Q4 2025, closing a stake of 26,213 shares — an estimated $376K sold.

GSA Capital Partners first reported a position in ATRA in Q1 2021 and held it in 10 quarters. The position peaked at $402K in Q4 2023. 41 funds tracked by Wall St. Rank hold ATRA as of Q4 2025.

  • GSA Capital Partners reported no remaining Atara Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • GSA Capital Partners sold 26,213 Atara Biotherapeutics shares in Q4 2025, an estimated $376K.
  • GSA Capital Partners first reported a position in Atara Biotherapeutics in Q1 2021 and held it in 10 quarters.
  • GSA Capital Partners's Atara Biotherapeutics position peaked at $402K in Q4 2023.
  • 41 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.